X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: Zyprexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $825.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 28, 2023
Details:
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Lead Product(s): Candesartan Cilexetil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Divestment January 04, 2021
Details:
AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.
Lead Product(s): Candesartan Cilexetil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Divestment October 30, 2020
Details:
The portfolio to be divested to Cheplapharm is comprised Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Recipient: Takeda Pharmaceutical
Deal Size: $562.0 million Upfront Cash: $562.0 million
Deal Type: Divestment September 08, 2020
Details:
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.
Lead Product(s): Alfacalcidol
Therapeutic Area: Nephrology Product Name: One-Alpha
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Leo Pharma
Deal Size: $357.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
